{{medical}}
{{Drugbox|Verifiedfields=changed|Watchedfields=changed|verifiedrevid=456689148|IUPAC_name=4-amino-''N''-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide|image=Amisulpride.svg|width=250px|image2=Amisulpride-xtal-1990-ball-and-stick-model.png|width2=250px

<!--Clinical data-->|tradename=Solian, others|Drugs.com={{drugs.com|international|amisulpride}}|pregnancy_AU=C|legal_AU=S4|legal_UK=POM|routes_of_administration=[[Oral_administration|By mouth]], [[intravenous_therapy|intravenous]]

<!--Pharmacokinetic data-->|bioavailability=48%<ref name=Rosenzweig>{{ cite journal |author1=Rosenzweig, P. |author2=Canal, M. |author3=Patat, A. |author4=Bergougnan, L. |author5=Zieleniuk, I. |author6=Bianchetti, G. | title = A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers | journal = Human Psychopharmacology | volume = 17 | issue = 1 | year = 2002 | pages = 1–13 | pmid = 12404702 | doi = 10.1002/hup.320 }}</ref><ref name = SOLIAN>{{cite web|title=PRODUCT INFORMATION SOLIAN® TABLETS and SOLUTION|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01659-3|website=TGA eBusiness Services|publisher=Sanofi-Aventis Australia Pty Ltd|accessdate=17 October 2013|format=PDF|date=9 September 2013}}</ref>|protein_bound=16%<ref name = SOLIAN/>|metabolism=Hepatic (minimal; most excreted unchanged)<ref name = SOLIAN/>|elimination_half-life=12 hours<ref name=Rosenzweig/>|excretion=[[Kidney|Renal]]<ref name=Rosenzweig/> (23–46%),<ref name = BT>{{cite journal|author=Caccia, S|title=Biotransformation of Post-Clozapine Antipsychotics Pharmacological Implications|journal=Clinical Pharmacokinetics|doi=10.2165/00003088-200038050-00002|pmid=10843459|volume=38|issue=5|date=May 2000|pages=393–414}}</ref><ref name = Dys>{{cite journal|title=Amisulpride: A Review of its Clinical Potential in Dysthymia|author1=Noble, S |author2=Benfield, P |journal=CNS Drugs|volume=12|issue=6|date=December 1999|doi=10.2165/00023210-199912060-00005|pages=471–483}}</ref> [[Feces|Faecal]]<ref name = SOLIAN/>

<!--Identifiers-->|CAS_number_Ref={{cascite|changed|??}}|CAS_number=71675-85-9|CAS_supplemental=|ATC_prefix=N05|ATC_suffix=AL05|PubChem=2159|IUPHAR_ligand=963|DrugBank_Ref={{drugbankcite|correct|drugbank}}|DrugBank=DB06288|ChemSpiderID_Ref={{chemspidercite|correct|chemspider}}|ChemSpiderID=2074|UNII_Ref={{fdacite|correct|FDA}}|UNII=8110R61I4U|KEGG_Ref={{keggcite|correct|kegg}}|KEGG=D07310|ChEBI_Ref={{ebicite|changed|EBI}}|ChEBI=64045|ChEMBL_Ref={{ebicite|correct|EBI}}|ChEMBL=243712

<!--Chemical data-->|C=17|H=27|N=3|O=4|S=1|molecular_weight=369.48 g/mol|SMILES=O=S(=O)(c1cc(c(OC)cc1N)C(=O)NCC2N(CC)CCC2)CC|StdInChI_Ref={{stdinchicite|correct|chemspider}}|StdInChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)|StdInChIKey_Ref={{stdinchicite|correct|chemspider}}|StdInChIKey=NTJOBXMMWNYJFB-UHFFFAOYSA-N}}
'''氨磺必利'''，又名'''阿米舒必利'''、'''索里昂'''（'''Solian'''），它是一种治疗[[精神分裂症|精神分裂症]]的[[抗精神病药|抗精神病药]]。在意大利，它也被以每天50mg的剂量来治疗[[心境恶劣障碍|心境恶劣]]。<ref name=":0">Pani, L; Gessa, GL (2002). [http://www.nature.com/mp/journal/v7/n3/pdf/4001040a.pdf "The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia"] (PDF). ''Molecular Psychiatry''. '''7''' (3): 247–253. doi:[[doi:10.1038/sj.mp.4001040|10.1038/sj.mp.4001040]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/11920152 11920152].</ref>通常地，它被归为第二代抗精神病药，就是所谓的非典型抗精神病药。化学上来说，它属于[[苯甲酰胺|苯甲酰胺]]类的，同其它的苯甲酰胺类抗精神病药（例如[[舒必利|舒必利]]）相似，它有可能会提高[[泌乳素|泌乳素]]的分泌的水平并升高血清泌乳素的量，从而导致没有[[月經週期|月經週期]]、[[乳房|乳房]]增大（甚至对于男性而言也会这样）、在没有哺乳的情况下[[泌乳|泌乳]]、[[生育力|生育力]]受损、[[勃起功能障碍|勃起功能障碍]]和[[乳房疼痛|乳房疼痛]]等，而且在很低的概率下，它会像典型抗精神病药一样引起运动障碍。<ref>Rossi, S, ed. (2013). ''Australian Medicines Handbook'' (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN [[:en:Special:BookSources/978-0-9805790-9-3|978-0-9805790-9-3]].</ref><ref name=":1">Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C; Engel, RR; Geddes, JR; Kissling, W; Stapf, MP; Lässig, B; Salanti, G; Davis, JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". ''Lancet''. '''382''' (9896): 951–962. doi:[[doi:10.1016/S0140-6736(13)60733-3|10.1016/S0140-6736(13)60733-3]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/23810019 23810019].</ref><ref>Brayfield, A, ed. (June 2017). [https://www.medicinescomplete.com/mc/martindale/current/1759-d.htm "Amisulpride: Martindale: The Complete Drug Reference"]. MedicineComplete. Pharmaceutical Press. Retrieved 5 August 2017.</ref>同典型抗精神病药相比，它对与精神分裂的疗效稍微好一些。<ref name=":1" />

同多数其他的被批准的抗精神病药一样，氨磺必利被认为是通过减少[[多巴胺|多巴胺]][[多巴胺受體D2|D<sub>2</sub>受体]]的信号传导而起作用的。对于氨磺必利而言，这是通过阻断或拮抗受体而做到的。氨磺必利治疗心境恶劣和精神分裂的阴性症状的功效据信是由于它阻断了突触前D<sub>2</sub>受体，使多巴胺脱抑制性释放，升高浓度的多巴胺作用于D<sub>1</sub>受体，从而缓解心境恶劣以及精神分裂的阴性症状。<ref name=":0" />

它由[[赛诺菲#%E8%B5%9B%E8%AF%BA%E8%8F%B2%EF%BC%8D%E5%AE%89%E4%B8%87%E7%89%B9|Sanofi-Avents]]在1990年代推向市场。它的专利已于2008年过期，因此现在有了[[通用名药物|通用名药物]]。它在除了加拿大和美国之外的所有英语国家出售。

== 医学用途 ==

=== 精神分裂 ===
2013年，一项研究比较了15种抗精神病药在治疗精神分裂方面的疗效，氨磺必利表现出了相当高的效力并排名第二。疗效比排名第三的[[奥氮平|奥氮平]]高11%，比[[氟哌啶醇|氟哌啶醇]]、[[喹硫平|喹硫平]]和[[阿立哌唑|阿立哌唑]]高32-35%，比排名第一的[[氯氮平|氯氮平]]低25%。<ref name=":1" />但是有一些研究指出在治疗精神分裂方面，氨磺必利的疗效与奥氮平相近。<ref>Komossa, K; Rummel-Kluge, C; Hunger, H; Schmid, F; Schwarz, S; Silveira da Mota Neto, JI; Kissling, W; Leucht, S (January 2010). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164462 "Amisulpride versus other atypical antipsychotics for schizophrenia"]. ''The Cochrane Database of Systematic Reviews'' (1): CD006624. doi:[[doi:10.1002/14651858.CD006624.pub2|10.1002/14651858.CD006624.pub2]]. PMC [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164462 4164462]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/20091599 20091599].</ref><ref>Leucht, S; Corves, C; Arbter, D; Engel, RR; Li, C; Davis, JM (January 2009). "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis". Lancet. 373 (9657): 31–41. doi:[[doi:10.1016/S0140-6736(08)61764-X|10.1016/S0140-6736(08)61764-X]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/19058842 19058842].</ref>就像联用舒必利那样联用氨磺必利来治疗氯氮平抵抗的难治性患者被认为是一种行之有效的选择。（虽然这种观点所基于的证据质量较低）<ref>Solanki, RK; Sing, P; Munshi, D (Oct–Dec 2009). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802371 "Current perspectives in the treatment of resistant schizophrenia"]. Indian Journal of Psychiatry. 51 (4): 254–60. doi:[[doi:10.4103/0019-5545.58289|10.4103/0019-5545.58289]]. PMC 2802371. PMID [https://www.ncbi.nlm.nih.gov/pubmed/20048449 20048449].</ref><ref>Mouaffak, F; Tranulis, C; Gourevitch, R; Poirier, MF; Douki, S; Olié, JP; Lôo, H; Gourion, D (2006). "Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia". Clinical Neuropharmacology. 29 (1): 28–33. doi:[[doi:10.1097/00002826-200601000-00009|10.1097/00002826-200601000-00009]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/16518132 16518132].</ref>最近，另一项研究表明氨磺必利是用于急性精神分裂的合理的一线选择。<ref>Nuss, P.; Hummer, M.; Tessier, C. (2007). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936283 "The use of amisulpride in the treatment of acute psychosis"]. Therapeutics and Clinical Risk Management. 3 (1): 3–11. doi:[[doi:10.2147/tcrm.2007.3.1.3|10.2147/tcrm.2007.3.1.3]]. PMC [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936283 1936283]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/18360610 18360610].</ref>

=== 心境恶劣与抑郁症 ===
有研究在有心境恶劣障碍的病患中在有安慰剂的情况下将氨磺必利与[[氟西汀|氟西汀]]、[[丙咪嗪|丙咪嗪]]、[[阿米替林|阿米替林]]和[[阿米庚酸|阿米庚酸]]相比较，临床观察显示氨磺必利可能有抗抑郁活性。<ref>Vishal Chhabra, Manjeet Singh Bhatia. [http://medind.nic.in/daa/t07/i2/daat07i2p140.pdf "Amisulpride: a Brief Review"](PDF) DELHI PSYCHIATRY JOURNAL Vol.10 No.2. OCTOBER 2007</ref>

以标准的抑郁评级为依据，在单独患有心境恶劣障碍的患者中，50mg/d的氨磺必利同25-75mg/d的阿米替林<ref>Ravizza L. [https://www.ncbi.nlm.nih.gov/pubmed/10512080 "Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators"].  ''Journal of Psychopharmacology''. 13(3):248-54 · February 1999. PMID: [https://www.ncbi.nlm.nih.gov/pubmed/10512080 10512080]</ref>和20mg/d的氟西汀<ref>Smeraldi, E. "[https://www.sciencedirect.com/science/article/pii/S0165032797001390 Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study"]. ''Journal of Affective Disorders'', Volume 48, Issue 1, 1998, Pages 47-56, ISSN [https://www.sciencedirect.com/science/article/pii/S0165032797001390 0165-0327].</ref>一样有效。两项安慰剂控制的实验在患有原发性心境恶劣和[[抑郁症|抑郁症]]的患者中，将氨磺必利与阿米庚酸（200mg/d）<ref>Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O: [https://www.ncbi.nlm.nih.gov/pubmed/9892856 Amisulpride versus Amineptine and Placebo for the Treatment of Dysthymia]. Neuropsychobiology 1999;39:25-32. doi: [https://www.ncbi.nlm.nih.gov/pubmed/9892856 10.1159/000026556]</ref>和丙咪嗪（100mg/d）<ref>{{Cite journal|title=Amisulpride versus imipramine and placebo in dysthymia and major depression|url=https://linkinghub.elsevier.com/retrieve/pii/S0165032796001036|last=Lecrubier|first=Y|last2=Boyer|first2=P|date=1997-04|journal=Journal of Affective Disorders|issue=2|doi=10.1016/s0165-0327(96)00103-6|volume=43|pages=95–103|issn=0165-0327|last3=Turjanski|first3=S|last4=Rein|first4=W}}</ref>相比较，结果显示氨磺必利同这些[[抗抑郁药|抗抑郁药]]同样有效。

氨磺必利可用于加速[[SSRI|SSRI]]的生效，一项针对[[汉密尔顿抑郁量表|汉密尔顿抑郁量表]]（HDRS）评分超过20的36岁以上（平均51.3岁）的女性患者的研究，在使用100mg/d的氟伏沙明的基础上增加50mg/d的氨磺必利，结果显示在第一周时，平均HDRS得分就与基线有显著差异（p=0.003）。<ref>{{Cite journal|title=Strategy to Accelerate or Augment the Antidepressant Response and for An Early Onset of SSRI Activity. Adjunctive Amisulpride to Fluvoxamine in Major Depressive Disorder|author=|url=https://benthamopen.com/FULLTEXT/CPEMH-6-1|last=Carolina|first=Hardoy Maria|last2=Giovanni|first2=Carta Mauro|date=2010-01-27|journal=Clinical Practice & Epidemiology in Mental Health|issue=1|doi=10.2174/1745017901006010001|others=|year=|volume=6|page=|pages=1–3|issn=1745-0179|pmid=20498696}}</ref>

=== 抑郁症引发的焦虑 ===
一项持续一年的研究将患者分为分别使用50mg/d的氨磺必利和10mg/d的艾斯西酞普兰的两组，实验进行到第十五周时，两组的HAMA分值与基线相比皆有显著差异，两组之间没有统计学差异，证明氨磺必利和艾斯西酞普兰同为治疗抑郁症引发的焦虑的有效药物。<ref>{{Cite journal|title=Comparative evaluation of amisulpride and escitalopram on Hamilton anxiety rating scale among depression patients in a tertiary care teaching hospital in Nepal|url=http://www.ijbcp.com/index.php/ijbcp/article/view/925|last=Kaul|first=Vijay|last2=Dutta|first2=Shakti B.|date=2017-01-21|journal=International Journal of Basic & Clinical Pharmacology|issue=2|doi=10.5455/2319-2003.ijbcp20150438|volume=4|pages=349–353|language=en|issn=2279-0780|last3=Beg|first3=Mirza A.|last4=Bawa|first4=Shalu|last5=Anjoom|first5=Mohammed|last6=Singh|first6=Nand K.|last7=Dutta|first7=Srihari}}</ref>

ʜ== 禁忌症 ==
在如下的情况下使用氨磺必利是禁忌的：

* 嗜铬细胞瘤
* 共病催乳素依赖性肿瘤，如催乳素瘤、[[乳腺癌|乳腺癌]]
* 运动障碍（例如[[帕金森氏症|帕金森氏症]]、[[路易氏体失智症|路易氏体失智症]]）
*[[哺乳期|哺乳期]]
* 进入[[青春期|青春期]]前的儿童

同时也不建议在对氨磺必利或其药剂的任何一种辅料过敏的人群中使用氨磺必利。

== 不良反应 ==

=== 很常见（发病率≥10％）<ref>Sandoz Limited [http://www.medicines.org.uk/emc/medicine/25321 Summary of Product Characteristics], [https://web.archive.org/web/20140817052520/http://www.medicines.org.uk/emc/medicine/25321/ archived] from the original on 2014-08-17, retrieved 2014-08-17</ref>===

*[[锥体外系副作用|锥体外系副作用]]（EPS；包括[[肌张力障碍|肌张力障碍]]、[[顫抖|震颤]]、[[静坐不能|静坐不能]]、[[帕金森氏症|帕金森氏症]]），氨磺必利会造成中等程度的EPS，效力高于阿立哌唑、氯氮平、[[伊潘立酮|伊潘立酮]]、奥氮平、喹硫平和[[舍吲哚|舍吲哚]]；低于[[氯丙嗪|氯丙嗪]]、[[氟哌啶醇|氟哌啶醇]]、[[鲁拉西酮|鲁拉西酮]]、[[帕利哌酮|帕利哌酮]]、[[利培酮|利培酮]]、[[齊拉西酮|齐拉西酮]]和[[佐替平|佐替平]]。

=== 常见（发病率≥1％且<10％）<ref name=":2">[https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01659-3 "PRODUCT INFORMATION SOLIAN® TABLETS and SOLUTION"] (PDF). TGA eBusiness Services. Sanofi-Aventis Australia Pty Ltd. 9 September 2013. Retrieved 17 October 2013.</ref><ref name=":3">Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Sep 19]. Greenwood Village, CO: Thomsen Healthcare; 2013.</ref><ref name=":4">Joint Formulary Committee (2013). ''British National Formulary (BNF)'' (65 ed.). London, UK: Pharmaceutical Press. ISBN [[:en:Special:BookSources/978-0-85711-084-8|978-0-85711-084-8]].</ref><ref name=":5">Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN [[:en:Special:BookSources/978-0-9805790-9-3|978-0-9805790-9-3]].</ref>===

*[[失眠|失眠]]

* 唾液分泌过多

*[[恶心|恶心]]

*[[頭痛|头痛]]

* 肺热

*[[焦虑症|焦虑]]

*[[呕吐|呕吐]]

*[[高催乳素血症|高催乳素血症]]（可导致乳糜泻、乳房增大和压痛、[[性功能障碍|性功能障碍]]等），高催乳素血症是由位于脑下垂体前叶中的催乳素细胞上的D<sub>2</sub>受体被拮抗作用引起的。由于氨磺必利穿过[[血腦屏障|血脑屏障]]的能力较差，拮抗外周D<sub>2</sub>受体的效力与中枢D<sub>2</sub>受体的比值较大，这意味着如果要达到治疗效果（中枢D<sub>2</sub>受体被拮抗约60-80%<ref>Brunton, L; Chabner, B; Knollman, B (2010). ''[[:en:Goodman_and_Gilman's_The_Pharmacological_Basis_of_Therapeutics|Goodman and Gilman's The Pharmacological Basis of Therapeutics]]'' (12th ed.). New York: McGraw-Hill Professional. ISBN [[:en:Special:BookSources/978-0-07-162442-8|978-0-07-162442-8]].</ref>），外周的氨磺必利浓度需要足够大，包括脑下垂体前叶中的D<sub>2</sub>受体便被大量拮抗，因此它有着较高的提升血清催乳素水平的倾向。<ref>McKeage, K; Plosker, GL (2004). "Amisulpride: a review of its use in the management of schizophrenia". ''CNS Drugs''. '''18''' (13): 933–956. doi:[[doi:10.2165/00023210-200418130-00007|10.2165/00023210-200418130-00007]]. ISSN [https://www.worldcat.org/issn/1172-7047 1172-7047]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/15521794 15521794].</ref><ref>Natesan, S; Reckless, GE; Barlow, KB; Nobrega, JN; Kapur, S (October 2008). "Amisulpride the 'atypical' atypical antipsychotic — Comparison to haloperidol, risperidone and clozapine". ''Schizophrenia Research''. '''105''' (1–3): 224–235. doi:[[doi:10.1016/j.schres.2008.07.005|10.1016/j.schres.2008.07.005]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/18710798 18710798].</ref>

* 体重增加，增加的重量比氯丙嗪、氯氮平，伊潘立酮、奥氮平、帕利哌酮、喹硫平、利培酮、舍吲哚、佐替平更少，比氟哌啶醇、鲁拉西酮、齐拉西酮、阿立哌唑和[[阿塞那平|阿塞那平]]更多。（虽然没有统计学意义）<ref name=":1" />

*[[抗胆碱能|抗胆碱能]]副作用（它不与[[蕈毒鹼型乙醯膽鹼受體|毒蕈碱乙酰胆碱受体]]结合，因此这些副作用通常很轻微），如：
**[[便秘|便秘]]
** 口干
** 视物模糊

=== 罕见（发病率<1％）<ref name=":2" /><ref name=":3" /><ref name=":4" /><ref name=":5" />===

*[[心跳过缓|心动过缓]]

*[[低血壓|低血压]]

*[[心悸|心悸]]

*[[荨麻疹|荨麻疹]]

*[[癫痫|癫痫]]发作

*[[狂躁|狂躁]]

* 眼动危象

*[[迟发性运动障碍|迟发性运动障碍]]

* 血液[[惡病質|恶液质]]，如[[白细胞减少症|白细胞减少症]]、[[中性粒细胞减少症|中性粒细胞减少症]]和[[粒细胞缺乏症|粒细胞缺乏症]]

*[[長QT綜合症|QT间期延长]]（在最近的一项对15种抗精神病药的安全性和有效性的荟萃​​分析中，发现氨磺必利对QT期延长的效应高居第二位。）

*[[嗜睡症|嗜睡]]。由于其不存在对[[胆碱|胆碱]]能、[[組織胺|组胺]]能和α[[肾上腺素|肾上腺素]]能受体拮抗作用，所以它的镇静效应很轻微。它是镇静效果最轻的抗精神病药物之一。<ref name=":1" />

== 药物过量 ==
尖端扭转型室性心动过速（Torsades de pointes，TdP）在过量服用中很常见，<ref>Isbister, GK; Balit, CR; Macleod, D; Duffull, SB (August 2010). "Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes". Journal of Clinical Psychopharmacology. 30 (4): 391–395. doi:[[doi:10.1097/JCP.0b013e3181e5c14c|10.1097/JCP.0b013e3181e5c14c]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/21716272 20531221].</ref><ref>Joy, JP; Coulter, CV; Duffull, SB; Isbister, GK (August 2011). "Prediction of Torsade de Pointes From the QT Interval: Analysis of a Case Series of Amisulpride Overdoses". Clinical Pharmacology & Therapeutics. 90 (2): 243–245. doi:[[doi:10.1038/clpt.2011.107|10.1038/clpt.2011.107]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/21716272 21716272].</ref>氨磺必利过量造成中等危险程度的TdP（[[三环类抗抑郁药|TCA]]造成高度危险的TdP，而[[选择性5-羟色胺再摄取抑制剂|SSRI]]只造成轻微的危险）。<ref name=":6">Taylor, D; Paton, C; Shitij, K (2012). ''Maudsley Prescribing Guidelines in Psychiatry'' (11th ed.). West Sussex: Wiley-Blackwell. ISBN [[:en:Special:BookSources/978-0-47-097948-8|978-0-47-097948-8]].</ref><ref>Levine, M; Ruha, AM (July 2012). "Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management". CNS Drugs. 26 (7): 601–611. doi:[[doi:10.2165/11631640-000000000-00000|10.2165/11631640-000000000-00000]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/22668123 22668123].</ref>

== 药物相互作用 ==
氨磺必利不应同延长QT间期的药物（例如[[西酞普兰|西酞普兰]]、[[文拉法辛|文拉法辛]]、[[安非他酮|安非他酮]]、氯氮平、TCA、舍吲哚和齐拉西酮等）<ref name=":6" />；降低心率的药物以及可诱发[[低鉀血症|低钾血症]]的药物一同使用。同样地，由于引发迟发性运动障碍和[[神经阻滞剂恶性综合征|神经阻滞剂恶性综合征]]的风险，氨磺必利与其他的抗精神病药的联用是不明智的。<ref name=":6" />

== 药理学 ==

=== 药效学 ===
{| class="wikitable floatright" style="font-size:small;"
|+氨磺必利<ref>Roth, BL; Driscol, J. "[https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=%20&receptorDD=%20&receptor=%20&speciesDD=%20&species=%20&sourcesDD=%20&source=%20&hotLigandDD=%20&hotLigand=%20&testLigandDD=%20&testFreeRadio=testFreeRadio&testLigand=amisulpride&referenceDD=%20&reference=%20&KiGreater=%20&KiLess=%20&kiAllRadio=all&doQuery=Submit+Query PDSP K<sub>i</sub> Database"]. ''Psychoactive Drug Screening Program (PDSP)''. University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.</ref><ref name=":7" />
!位点
!K<sub>i</sub>（nM）
!物种
!引用
|-
|5-HT<sub>1A</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|5-HT<sub>1B</sub>
|1,744
|人类
|<ref name=":7" />
|-
|5-HT<sub>1E</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|5-HT<sub>2A</sub>
|8,304
|人类
|<ref name=":7" />
|-
|'''5-HT<sub>2B</sub>'''
|'''13'''
|'''人类'''
|<ref name=":7" />
|-
|5-HT<sub>2C</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|5-HT<sub>3</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|5-HT<sub>5A</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|5-HT<sub>6</sub>
|4,154
|人类
|<ref name=":7" />
|-
|'''5-HT<sub>7</sub>'''
|'''11.5'''
|'''人类'''
|<ref name=":7" />
|-
|α<sub>1A</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|α<sub>1B</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|α<sub>1D</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|α<sub>2A</sub>
|1,114
|人类
|<ref name=":7" />
|-
|α<sub>2C</sub>
|1,540
|人类
|<ref name=":7" />
|-
|[[Β1腎上腺素受體刺激劑|β<sub>1</sub>]]
|>10,000
|人类
|<ref name=":7" />
|-
|β<sub>2</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|β<sub>3</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|D<sub>1</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|'''D<sub>2</sub>'''
|'''3.0'''
|'''人类'''
|<ref name=":7" />
|-
|'''D<sub>3</sub>'''
|'''3.5'''
|'''大鼠'''
|<ref name=":7" />
|-
|D<sub>4</sub>
|2,369
|人类
|<ref name=":7" />
|-
|D<sub>5</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|H<sub>1</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|H<sub>2</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|H<sub>4</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|M<sub>1</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|M<sub>2</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|M<sub>3</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|M<sub>4</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|M<sub>5</sub>
|>10,000
|人类
|<ref name=":7" />
|-
|σ<sub>1</sub>
|>10,000
|大鼠
|<ref name=":7" />
|-
|σ<sub>2</sub>
|>10,000
|大鼠
|<ref name=":7" />
|-
|<abbr>MOR</abbr>
|>10,000
|人类
|<ref name=":7" />
|-
|<abbr>DOR</abbr>
|>10,000
|人类
|<ref name=":7" />
|-
|<abbr>KOR</abbr>
|>10,000
|人类
|<ref name=":7" />
|-
|<abbr>'''GHB<sup>High</sup>'''</abbr>
|'''50 (<abbr>IC<sub>50</sub></abbr>)'''
|'''大鼠'''
|<ref name=":8" />
|-
|<abbr>NMDA</abbr>(<abbr>PCP</abbr>)
|>10,000
|大鼠
|<ref>Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997). "Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity". ''J. Pharmacol. Exp. Ther''. '''280'''(1): 83–97. PMID [https://www.ncbi.nlm.nih.gov/pubmed/8996185 8996185].</ref>
|-
|<abbr>SERT</abbr>
|>10,000
|人类
|<ref name=":7" />
|-
|<abbr>NET</abbr>
|>10,000
|人类
|<ref name=":7" />
|-
|<abbr>DAT</abbr>
|>10,000
|人类
|<ref name=":7" />
|-
| colspan="4" |数值为K<sub>i</sub>（nM）。数值越小，药物对此位点的结合越强
|}
氨磺必利主要作为D<sub>2</sub>和D<sub>3</sub>受体的[[受体拮抗剂|拮抗剂]]而起作用。它对这些受体有高[[親和力|亲和力]]，[[解离常数|解离常数]]（K<sub>i</sub>）分别为3.0和3.5nM。虽然在用于治疗精神分裂症的剂量下它会抑制多巴胺能的传递，但是在低剂量下它会优先阻滞突触前多巴胺自身受体，导致多巴胺脱抑制性释放，增加多巴胺能，因此，低剂量氨磺必利也被用于治疗心境恶劣和抑郁症。<ref name=":2" /><ref>Cassano, G. B.a; Jori, M. C.b. "[https://journals.lww.com/intclinpsychopharm/Abstract/2002/01000/Efficacy_and_safety_of_amisulpride_50_mg_versus.4.aspx Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study"]. ''International Clinical Psychopharmacology'': January 2002 - Volume 17 - Issue 1 - p 27-32</ref>

在治疗浓度下（对氨磺必利而言IC<sub>50</sub>=50nM），氨磺必利和它的近亲[[舒必利|舒必利]]、[[左旋舒必利|左旋舒必利]]和[[舒托必利|舒托必利]]都显示出了与[[Γ-羟基丁酸|GHB]]受体的高亲和力的结合<ref name=":8">Maitre, M.; Ratomponirina, C.; Gobaille, S.; Hodé, Y.; Hechler, V. (Apr 1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". ''European Journal of Pharmacology''. '''256''' (2): 211–214. doi:[[doi:10.1016/0014-2999(94)90248-8|10.1016/0014-2999(94)90248-8]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/7914168 7914168].</ref>

氨磺必利、舒托必利和舒必利在试管中对D<sub>2</sub>受体（IC<sub>50</sub>分别为27、120和181nM）和D<sub>3</sub>受体（IC<sub>50</sub>分别为3.6、4.8和17.5）的亲和力依次降低。<ref>Blomme, Audrey; Conraux, Laurence; Poirier, Philippe; Olivier, Anne; Koenig, Jean-Jacques; Sevrin, Mireille; Durant, François; George, Pascal (2000), [https://link.springer.com/chapter/10.1007/978-1-4615-4141-7_97 "Amisulpride, Sultopride and Sulpiride: Comparison of Conformational and Physico-Chemical Properties"], ''Molecular Modeling and Prediction of Bioactivity'', Springer US, pp. 404–405, doi:[[doi:10.1007/978-1-4615-4141-7_97|10.1007/978-1-4615-4141-7_97]], ISBN [[:en:Special:BookSources/9781461368571|9781461368571]], retrieved 2018-09-21</ref>

虽然长期以来人们普遍认为对多巴胺能的调节是氨磺必利抗抑郁和抗精神病的唯一原因，但随后发现它也是[[5-羟色胺|5-羟色胺]][[5-HT7受体|5-HT<sub>7</sub>受体]]的有效的拮抗剂（K<sub>i</sub>=11.5nM）。<ref name=":7">Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (2009). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821721 "Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo"]. ''Psychopharmacology''. '''205''' (1): 119–28. doi:[[doi:10.1007/s00213-009-1521-8|10.1007/s00213-009-1521-8]]. PMC [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821721 2821721]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/19337725 19337725].</ref>几种其他的非典型抗精神病药，例如利培酮和齐拉西酮，也是5-HT<sub>7</sub>受体的有效的拮抗剂，而且选择性地拮抗5-HT<sub>7</sub>受体本身也显示出了抗抑郁效果。一项实验制备了5-HT<sub>7</sub>受体敲除的小鼠，以表明5-HT<sub>7</sub>受体在氨磺必利的抗抑郁作用中的角色。<ref name=":7" />该研究发现，在两种广泛使用的[[啮齿动物|啮齿动物]]抑郁症模型中，即在尾部悬吊试验和强迫游泳试验中，这些小鼠在用氨磺必利治疗后没有表现出抗抑郁反应。<ref name=":7" />表明氨磺必利的抗抑郁效应是由5-HT<sub>7</sub>受体介导的。<ref name=":7" />

氨磺必利似乎也以高亲和力与[[5-HT2B受體|5-HT<sub>2B</sub>受体]]结合（K<sub>i</sub>=13nM），充当一种拮抗剂。<ref name=":7" />这一点的临床意义（如果有的话）尚不清楚。<ref name=":7" />无论如何，没有证据表明这种作用可以介导氨磺必利的任何治疗作用。<ref name=":7" />

== 社会与文化 ==

=== 商品名 ===
商品名包括：Amazeo、Amipride （[[澳大利亚|澳大利亚]]）、Amival、Solian （澳大利亚，[[爱尔兰|爱尔兰]]，[[俄罗斯|俄罗斯]]，[[英国|英国]]，[[南非|南非]]）、Soltus、Sulpitac （[[印度|印度]]）、Sulprix （澳大利亚）、Midora（[[羅馬尼亞|罗马尼亚]]）和Socian （[[巴西|巴西]]）。

=== 可用性 ===
在中国，氨磺必利被批准用于治疗精神分裂症，氨磺必利在[[美国|美国]]未被[[美国食品药品监督管理局|FDA]]批准，但在[[欧洲|欧洲]]（[[法国|法国]]、[[德国|德国]]、[[意大利|意大利]]、[[瑞士|瑞士]]、俄罗斯、英国等）；[[以色列|以色列]]；[[墨西哥|墨西哥]]；印度；[[新西兰|新西兰]]和澳大利亚（TGA于2002年2月批准）被批准治疗[[思覺失調|思觉失调]]和精神分裂症。<ref>Lecrubier, Y.; et al. (2001). "Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia". ''Neuropsychobiology''. '''44''' (1): 41–46. doi:[[doi:10.1159/000054913|10.1159/000054913]]. PMID [https://www.ncbi.nlm.nih.gov/pubmed/11408792 11408792].</ref><ref>Kaplan, A. (2004). [http://www.psychiatrictimes.com/showArticle.jhtml?articleID=175802519 "Psychotropic Medications Around the World"]. ''Psychiatric Times''. '''21''' (5).</ref>

==參考文獻==
{{Reflist}}

[[Category:血清素拮抗剂|Category:血清素拮抗剂]]
[[Category:苯胺|Category:苯胺]]
[[Category:抗抑郁药物|Category:抗抑郁药物]]
[[Category:非典型抗精神病药|Category:非典型抗精神病药]]
[[Category:苯酰胺类|Category:苯酰胺类]]
[[Category:多巴胺拮抗药|Category:多巴胺拮抗药]]
[[Category:各作用機制精神藥物|Category:各作用機制精神藥物]]
[[Category:芳香醚|Category:芳香醚]]
[[Category:吡咯烷|Category:吡咯烷]]
[[Category:砜|Category:砜]]